Drug intelligence / Profile preview

KRX-107

Development stage: Preclinical
Lead developer: KinaRx
Modality: Small Molecules

Overview

KRX-107 is a small-molecule inhibitor of the Fms-like tyrosine kinase 3 (FLT3) being developed by KinaRx for the treatment of Acute Myeloid Leukemia (AML). The compound is specifically designed to target FLT3 mutations, including gatekeeper and secondary mutations that confer resistance to currently approved FLT3 inhibitors. KRX-107 is KinaRx's lead compound and is currently in preclinical safety studies. The drug aims to address the clinical challenge of relapse in AML patients who develop resistance to first- and second-generation FLT3 inhibitors.

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on KRX-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRX-107.

Explore the full profile